Differential Effects of the Antimuscarinic Agents Darifenacin and Oxybutynin ER on Memory in Older Subjects

European Urology

Volumn 50, Issue 2, 2006, Pages 317-326

  Kay, Gary ^a   Crook, Thomas ^b   Rekeda, Ludmyla ^c   Lima, Raul ^c   Ebinger, Ursula ^c   Arguinzoniz, Miguel ^c   Steel, Michael ^c  

^a Washington Neuropsychological Institute   (United States)

^b Psychologix Inc   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antimuscarinic; Cognitive function; Darifenacin; Older subjects; Oxybutynin ER

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG LABELING; DYSPEPSIA; FEMALE; HUMAN; MALE; MEMORY; MEMORY DISORDER; MENTAL TEST; MULTICENTER STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; SENESCENCE; XEROSTOMIA;

AGED; ANALYSIS OF VARIANCE; ATTENTION; BENZOFURANS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MEMORY DISORDERS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; PYRROLIDINES; REACTION TIME; URINARY BLADDER, OVERACTIVE;

EID: 33745861002     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.03.057     Document Type: Article

References (30)

1. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thuroff J., and Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 (2001) 760-766
2. 3 receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 21 (2001) 243-248
3. Ouslander J.G. Management of overactive bladder. N Engl J Med 350 (2004) 786-799
4. Crook T.H., Lebowitz D., Pirozzolo F.J., et al. Recalling names after introduction: changes across the adult life span in two cultures. Development Neuropsychol 9 (1993) 103-113
5. Norbury R., Travis M.J., Erlandsson K., et al. SPET imaging of central muscarinic receptors with (R,R) [123I]-I-QNB: methodological considerations. Nucl Med Biol 31 (2004) 583-590
6. Sunderland T., Tariot P.N., Cohen R.M., Weingartner H., Mueller III E.A., and Murphy D.L. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose response study. Arch Gen Psychiatry 44 (1987) 418-426
7. Flicker C., Ferris S.H., and Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology 107 (1992) 437-441
8. Molchan S.E., Martinez R.A., Hill J.L., et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 17 (1992) 215-226
9. 3 receptor subtype. Neurourol Urodyn 21 (2002) A445
10. 1 muscarinic receptor mutant mice. Nat Neurosci 6 (2003) 51-58
11. Drachman D.A., Noffsinger D., Sahakian B.J., Kurdziel S., and Fleming P. Aging, memory, and the cholinergic system: A study of dichotic listening. Neurobiol Aging 1 (1980) 39-43
12. 3 receptor selectivity. Eur Urol Suppl 1 4 (2002) 23-28
13. 3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 96 (2005) 1055-1062
14. Lipton R.B., Kolodner K., and Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 173 (2005) 493-498
15. Katz I.R., Sands L.P., Bilker W., DiFilippo S., Boyce A., and D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 46 (1998) 8-13
16. ® (oxybutynin chloride) Extended Release Tablets. Prescribing Information. Ortho-McNeil Pharmaceutical, Inc., June 2004 (available at: http://www.ditropanxl.com/professional/full_presc.htm).
17. ® (darifenacin) Extended Release Tablets. Prescribing Information. Novartis Pharmaceuticals Corporation, December 2004 (available at: http://www.pharma.us.novartis.com/product/pi/pdf/enablex.pdf).
18. Crook III T.H., and Larrabee G.J. A self-rating scale for evaluating memory in everyday life. Psychol Aging 5 (1990) 48-57
19. Youngjohn J.R., Larrabee G.J., and Crook T.H. First-last Names and Grocery List Selective Reminding Test: two computerized measures of everyday verbal learning. Arch Clin Neuropsychol 6 (1991) 287-300
20. Crook T.H., and West R.L. Name recall performance across the adult life-span. Br J Psychol 81 Pt. 3 (1990) 335-349
21. Nickelsen T., Lufkin E.G., Riggs B.L., Cox D.A., and Crook T.H. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24 (1999) 115-128
22. Crook III T.H., Youngjohn J.R., Larrabee G.J., and Salama M. Aging and everyday memory: a cross-cultural study. Neuropsychol 6 (1992) 123-136
23. Crook III T.H., Youngjohn J.R., and Larrabee G.J. The misplaced objects test: a measure of everyday visual memory. J Clin Exp Neuropsychol 12 (1990) 819-833
24. Coffey D.J., Jenkyn L.R., Coffey A.K., and Wells B.B. Sertraline vs amitriptyline vs placebo: effects on cognitive and motor functioning in the elderly. Neuropsychopharmacology 10 Suppl 2 (1994) 222S
25. Skerjanec A., and Devineni D. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 45 (2006) 325-350
26. Volpicelli L.A., and Levey A.I. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 145 (2004) 59-66
27. 3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 95 (2005) 993-1001
28. 3 selective receptor antagonist. Eur Urol 48 (2005) 471-477
29. Power A.E., Vazdarjanova A., and McGaugh J.L. Muscarinic cholinergic influences in memory consolidation. Neurobiol Learn Mem 80 (2003) 178-193
30. Scheife R., and Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27 (2005) 144-153